Ipha

13 results

Pfizer’s Enbrel lost patent protection in Europe earlier this year. Biogen introduced Benepali into the Irish market in September
Pfizer cuts price of Enbrel to match rival ‘biosimilar’ drug

The price of one of the world’s most popular drugs is falling 30 per cent in Ireland under the terms of a recently signed pricing agreement. Enbrel,(...)

Where a generic medicine is a cheaper identical “copy” of a branded traditional small molecule drug, biosimilar are “me-too” versions of modern, large molecule complex biologic medicines
Biosimilar drugs win backing in landmark patient study

Switching from a branded biologic drug to a cheaper “biosimilar” makes no meaningful difference to patients suffering from a series of chronic inflamm(...)

The HEA has written to Minister for Health Simon Harris expressing its concern over what it calls the “biosimilar blocker”. Photograph: Dave Meehan
‘Biosimilar blocker’ clause could cost HSE over €50m a year

The Health Services Executive could lose out on savings of more than €50 million a year on just three widely used drugs under the terms of the new Med(...)

  • « First
  • ‹ Prev
  • 1
  • 2